Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations). Daxor Corporation developed and market the BVA-100® (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor's vision is optimal blood volume for all.
Company profile
Ticker
DXR
Exchange
Website
CEO
Michael R. Feldschuh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
132682108
DXR stock data
Latest filings (excl ownership)
8-K
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
25 May 23
N-CEN
Annual report (registered investment company)
16 Mar 23
N-CSR
Certified annual shareholder report (management investment company)
1 Mar 23
8-K
Daxor Corporation Announces Closing of $2.1 million Underwritten Public Offering and Exercise of Over-Allotment Option
21 Nov 22
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
14 Nov 22
N-PX
Annual report of proxy voting record
29 Aug 22
N-CSRS
Certified semi-annual shareholder report (management investment company)
25 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
29 Jun 22
DEF 14A
Definitive proxy
31 May 22
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
2 May 22
Transcripts
Latest ownership filings
NT NPORT-P
None (Mar 2023 report)
31 May 23
4
Michael Richard Feldschuh
25 May 23
4
Joy S. Goudie
25 May 23
NPORT-P
None (Sep 2022 report)
25 Nov 22
4
Caleb DesRosiers
18 Nov 22
4
Robert J Michel
18 Nov 22
4
JAMES A LOMBARD
27 Jun 22
4
Henry D. Cremisi
27 Jun 22
4
Joy S. Goudie
27 Jun 22
4
Edward Feuer
27 Jun 22
Institutional ownership, Q4 2022
1.6% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 5 |
| Opened positions | 1 |
| Closed positions | 1 |
| Increased positions | 1 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 435.31 mm |
| Total shares | 65.65 k |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Vanguard | 47.33 k | $433.53 mm |
| Renaissance Technologies | 17.12 k | $157.00 k |
| Tower Research Capital | 1.02 k | $9.00 k |
| MS Morgan Stanley | 175.00 | $1.60 mm |
| BAC Bank Of America | 1.00 | $9.00 k |
| WFC Wells Fargo & Co. | 0.00 | $0.00 |
| Proequities | 0.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 24 May 23 | Joy S. Goudie | Common Stock | Buy | Acquire P | No | No | 9.75 | 300 | 2.93 k | 300 |
| 24 May 23 | Feldschuh Michael Richard | Common Stock | Buy | Acquire P | No | No | 9.75 | 2,000 | 19.50 k | 160,206 |
| 18 Nov 22 | Robert J Michel | Daxor Common Stock | Buy | Acquire P | No | No | 10 | 1,000 | 10.00 k | 7,250 |
| 17 Nov 22 | Caleb DesRosiers | Daxor Common Stock | Buy | Acquire P | No | No | 9.5 | 3,157 | 29.99 k | 3,157 |
| 23 Jun 22 | Caleb DesRosiers | Stock options Common Stock | Grant | Acquire A | No | No | 13.09 | 4,000 | 52.36 k | 4,000 |
News
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
22 May 23
Daxor Corporation Announces Pricing Of $4M Underwritten Public Offering Of 410,260 Shares Of Its Common Stock At A Price Of $9.75/Share
22 May 23
Why Immix Biopharma Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
22 May 23
New Study Demonstrates Clinical Utility Of Daxor's Blood Volume Diagnostic In Heart Failure Outcomes
18 May 23
Daxor Announces Five New Hospitals Have Implemented Its BVA-100 Blood Volume Diagnostic For Clinical Use To Guide Fluid Management In Heart Failure Patients During The First Quarter Of 2023.
27 Mar 23
Press releases
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
25 May 23
Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
22 May 23
New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure
20 Apr 23
Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
13 Apr 23
New Study Confirms Daxor's BVA-100® Volume Metric Compared to CardioMEMS® Pressure Metric Has Unique Clinical Utility as a Diagnostic for Heart Failure Patients
23 Mar 23